UBS Group’s Regenxbio RGNX Stock Holding History

UBS Group’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-49,300	Closed	-$885K	–	9905
2023 Q4	$885K	Hold	49,300	–	–	﹤0.01%	4610
2023 Q3	$811K	Hold	49,300	–	–	﹤0.01%	4272
2023 Q2	$986K	Buy	+49,300	New	+$950K	﹤0.01%	4257
2021 Q4	–	Sell	-41,338	Closed	-$1.73M	–	10628
2021 Q3	$1.73M	Buy	+41,338	New	+$1.49M	﹤0.01%	3696
2018 Q4	–	Sell	-500	Closed	-$38K	–	8246
2018 Q3	$38K	Hold	500	–	–	﹤0.01%	6375
2018 Q2	$36K	Buy	+500	New	+$23.9K	﹤0.01%	6257

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

UBS Group's RGNX Position: Q2 2026 in Review

UBS Group reduced its Regenxbio (RGNX) stake by 2.9% in Q2 2026, selling an estimated $62.4K and leaving 249,947 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #4696.

UBS Group first reported a position in RGNX in Q3 2015 and has held it in 41 quarters since. The position peaked at $26.8M in Q4 2019. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

UBS Group held 249,947 shares of Regenxbio worth $2.99M as of Q2 2026.
UBS Group sold 7,516 Regenxbio shares in Q2 2026, an estimated $62.4K.
Regenxbio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4696 holding.
UBS Group first reported a position in Regenxbio in Q3 2015 and has held it in 41 quarters since.
UBS Group's Regenxbio position peaked at $26.8M in Q4 2019.
165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.